ASCRS 2026: Opus Genetics' Phentolamine Eye Drop Data Preview

Key Takeaways

• Opus Genetics will present Phase 3 data on phentolamine ophthalmic solution at the ASCRS Annual Meeting 2026.
• Presentations will cover the VEGA-3 study (presbyopia), LYNX-2 study (post-refractive surgery), and MIRA-2 study (mydriasis reversal).
• The focus will be on the efficacy and safety of phentolamine ophthalmic solution in improving vision in various patient populations.

Opus Genetics, Inc. (Nasdaq: IRD) is set to present data from its Phase 3 clinical trials of phentolamine ophthalmic solution 0.75% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026. The presentations will cover three distinct studies: VEGA-3, LYNX-2, and MIRA-2, each evaluating phentolamine ophthalmic solution for different indications.

The ASCRS Annual Meeting is a major event for ophthalmologists and vision scientists, providing a platform to share the latest research and advancements in cataract and refractive surgery. Opus Genetics' presentations are anticipated to draw significant attention due to the potential of phentolamine ophthalmic solution to address unmet needs in presbyopia, impaired mesopic vision post-refractive surgery, and mydriasis reversal.

Opus Genetics' Phentolamine Presentations

Opus Genetics will deliver three presentations at the ASCRS 2026 meeting:

• VEGA-3: An oral presentation (Abstract 119626) on Saturday, April 11, from 8:00–8:05 a.m. ET, will detail the Phase 3 study results of phentolamine ophthalmic solution for improving distance corrected near vision in presbyopic patients. The presentation is titled "Phentolamine Ophthalmic Solution Provides Durable Improvement in Distance Corrected Near Vision for Presbyopic Patients in a Phase 3 Study."
• LYNX-2: Another oral presentation (Abstract 119714) on Saturday, April 11, from 8:20–8:25 a.m. ET, will cover the Phase 3 randomized controlled study of phentolamine ophthalmic solution in post-refractive surgery patients with impaired mesopic vision. The presentation is titled "Phase 3 Randomized Controlled Study of Phentolamine Ophthalmic Solution in Post-Refractive Surgery Patients with Impaired Mesopic Vision."
• MIRA-2: An electronic poster (Abstract 123806), available on-demand starting Friday, April 10, will discuss the optical impact of reversing pharmacologically induced mydriasis on image quality. The poster is titled "Optical Impact of Reversing Pharmacologically Induced Mydriasis on Image Quality."

Phentolamine Ophthalmic Solution: Mechanism of Action

Phentolamine ophthalmic solution (0.75%) is an alpha-adrenergic antagonist. It is designed to improve vision by affecting pupil size and potentially improving accommodation. By inducing a slight miosis (pupil constriction), phentolamine can enhance depth of focus, thereby improving near and intermediate vision without significantly compromising distance vision. This mechanism of action differs from other treatments for presbyopia, such as reading glasses or multifocal lenses, which rely on refractive correction.

Market Impact and Future Outlook

If approved, phentolamine ophthalmic solution could capture a significant share of the presbyopia and vision correction market. The potential market includes a large population of individuals with presbyopia, as well as those experiencing impaired mesopic vision after refractive surgery. Opus Genetics' development plans will likely focus on securing regulatory approval and establishing commercial partnerships to bring phentolamine ophthalmic solution to market.

What to Watch Next

Key developments to watch include:

• Regulatory submissions and potential FDA approval of phentolamine ophthalmic solution.
• Further clinical trials exploring phentolamine's efficacy in other vision-related conditions.
• Commercialization strategies and market uptake following potential approval.

Frequently Asked Questions

• What is phentolamine ophthalmic solution?

  Phentolamine ophthalmic solution is a topical eye drop being developed by Opus Genetics to improve vision in conditions like presbyopia, impaired mesopic vision, and mydriasis.

• What are the VEGA-3, LYNX-2, and MIRA-2 studies?

  These are Phase 3 clinical trials evaluating phentolamine ophthalmic solution for presbyopia (VEGA-3), impaired mesopic vision post-refractive surgery (LYNX-2), and mydriasis reversal (MIRA-2).

• When will the data from these studies be presented?

  The data will be presented at the ASCRS Annual Meeting, April 10-13, 2026, in Washington, D.C.

• How does phentolamine ophthalmic solution work?

  It works by affecting pupil size, potentially improving accommodation and enhancing depth of focus.

• What is the potential market impact of this drug?

  If approved, phentolamine ophthalmic solution could address significant unmet needs in the presbyopia and vision correction market.

References

• Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting. Opus Genetics Investor Relations. https://ir.opusgtx.com/press-releases/detail/525/opus-genetics-announces-data-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-annual-meeting